Yue G.

• Lake Bleu Capital (清池资本) is a multi-billion dollar asset management platform operating in Hong Kong and Shanghai. We specialize in healthcare investment in Asia/Greater China • Full-Cycle Deal Experience Sole lead deal o Biocytogen 百奥赛图02315.HK - CRO/Biotech, Cross-over lead, late stage o Exegenesis Bio 嘉因生物 & CoJourney行诚生物 - Biotech/CDMO, Series B++ & Series A co- investment, growth & early stage o MediTrust Health 镁信健康 - Healthcare insurance - Series C co-investment, late stage o Vision X 艾康特- Optometry medical equipment - Series B&B+ co-investment, late stage o Bangbang Robotics 邦邦机器人 - Mobility Power Chair - Series B&B+ lead, growth stage o Phil Stone Biotech 贤石医疗 - Regenerative Biomaterials – Series A lead, early stage o Centre Medical 贤德医疗 - Cardiology Clinic - Series A lead, early stage o HC Scientific (Chengdu) L.L.C. 瀚辰光翼 - Modern Agriculture - Series B+ lead, growth stage o Banger Orthopaedic Hospital Group 邦尔骨科 - Orthopedic Hospital - pre-IPO co- investment, late stage o MolBreeding 博瑞迪 - Molecular Breeding in Agriculture - Series B co-investment, growth stage Assisted deal o WeMed 唯迈医疗- Interventional imaging medical equipment - Series D lead, late stage o Singleron 新格元 - Single cell platform - Series B lead, late stage Post investment management o BrioHealth Solutions 同心医疗 - LVAD for Heart Failure, late stage o Airdoc 鹰瞳医疗02251.HK - AI-based retinal imaging, IPO

• VMS Investment Group is a multi-strategies investment firm with businesses covering proprietary investments, asset management, securities brokerage, and corporate finance advisory. • Areas of focus: biotech, pharmaceuticals, contract manufacturing • Deal/Company Formation Experience I-Mab 天境生物 - Pharmaceuticals: innovative biologics for cancer immunotherapy and autoimmune diseases, Series C+ led Chime Biologics (JHL Biotech 喜康生物) - Biologics CDMO • Engaged in full project management cycle incl. sourcing, DD, deal structuring, transaction execution, operational & financial monitoring, contributing to strategy development, screening exit opportunities

• Market tracking: (1) build financial models to size the market and identify growth across 7 product categories for a global leading clinical diagnostics company; (2) track quarterly market sales value of major competitors including sales performance and key strategic moves, new product/pipeline for a global medical technology company • Market access: (1) assess and prioritize 14 APAC countries to support plasma fractionation market growth for a life science manufacture leader; (2) scan provincial pricing landscape and trend, including benchmarking of pricing levels of comparable products, build a short-term and long-term strategy for an innovative IVD kit • Health policy: draft EIU publication about fertility in China by literature review, secondary research, and KOL interviews. Publication: "Moving on from one How can China manage its declining fertility?" https://www.merckgroup.com/company/responsibility/our-cr-strategy/health/building-asian-families/en/Moving_on_from_one_English.pdf

• Conducted due diligence for a top global investment firm, performed portfolio prioritization analysis via screening and ranking 294 biological targets, 12 treatment areas, forecasted 2030 revenue of the 51 top-line and 7 high-potential drugs • Analyzed new drug registration system and approval process, production modes, sales plan, and generated China market entry models for a US pharma

Best oral presentation prize Research on exosomes, microvesicles, proteinomics, and cancer biology

Digitalized the medical record of infertility treatment and built a database of 1107 couples, improving efficiency by 30%; Developed a predictive model to prevent the occurrence of complications with an estimated cost savings of $8144 per patient; Optimized treatment regimen to prevent the anticipatory rise of serum progesterone level during the treatment resulting in an increased pregnancy rate of 13%

Consulted over 2000+ outpatients and managed 120+ inpatients per month while mentoring junior interns in clinical skills and negotiation techniques Conduct chart review and quantitative data analysis on 107 antibiotic resistant patients to assess the antibiotic drug usage in Central China and track their outcomes

Research: Identified a target protein in the pathogenesis of pregnancy-induced hypertension and applied in non-invasive prenatal diagnosis using latest biotechnologies such as nanoparticles, protein purification and identification

Combined Bachelor's and Master's Degree Graduated top 10% of class, National Scholarship for Academic Excellence awarded to top 1%